Prothena (PRTA)
(Delayed Data from NSDQ)
$21.01 USD
+0.40 (1.94%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $20.98 -0.03 (-0.14%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
PRTA 21.01 +0.40(1.94%)
Will PRTA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PRTA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRTA
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
PRTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
Other News for PRTA
Prothena (PRTA) Receives a Hold from RBC Capital
Prothena: Potential For Future Price Drop On Failure Risk Of Late-Stage Trials
Buy Rating Affirmed for Prothena Amid Strong Pipeline Prospects and Strategic Partnerships
Prothena (PRTA) Receives a Buy from Piper Sandler
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration